Analyst Rating
based on 18 analysts
44.44%
Buy
16.67%
Hold
38.89%
Sell
Based on 18 analysts offering long term price targets for Biocon Ltd. An average target of ₹335.06
Source: S&P Global Market Intelligence
Biocon Ltd Share analysis
Biocon Ltd price forecast by 18 analysts
Downside of
High
₹466
Target
₹335.06
Low
₹230
Biocon Ltd target price ₹335.06, a slight downside of -7.86% compared to current price of ₹361.5. According to 18 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Biocon Ltd revenue growth forecast
Expected growth rate Q1, FY2026:25.39%
Forecast
Actual
Including amortisation and stock based compensations
Biocon Ltd EPS growth forecast
EPS estimate Q1, FY2026:40.02%
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹351₹36952 Week's Low
52 Week's High
₹217.5₹395.8
| Returns % | |
| 1 Month Return | + 5.47 % |
| 3 Month Return | + 9.45 % |
| 1 Year Return | + 33.11 % |
| Market Stats | |
| Previous Close | ₹363.65 |
| Open | ₹365.00 |
| Volume | 63.51L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹43,659.82Cr |
Key Statistics
| P/E Ratio | 27.53 |
| PEG Ratio | 2.84 |
| Market Cap | ₹43,659.82 Cr |
| P/B Ratio | 2.91 |
| EPS | 10.81 |
| Dividend Yield | 0.19 |
| Sector | Pharmaceuticals |
| ROE | 0.97 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹43,659.82 Cr | 12% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹1,45,188.75 Cr | 49.12% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,13,699.02 Cr | 58.95% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹30,339.03 Cr | 0.24% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| BUY | ₹1,33,377.76 Cr | 53.07% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Company Information
Biocon's top products include insulin, monoclonal antibodies, enzymes, and vaccines. Its popular brands include Insugen, Insupen, and Insugen Plus. The company has a strong presence in the Indian market and is expanding its reach to other countries. Biocon has also established its presence in the US, Europe, and Japan.
Share Price: ₹361.50 per share as on 19 Sep, 2024 04:01 PM
Market Capitalisation: ₹43,659.82Cr as of today
Revenue: ₹3,432.90Cr as on June 2024 (Q2 24)
Net Profit: ₹861.80Cr as on June 2024 (Q2 24)
Listing date: 07 Apr, 2004
Chairperson Name: Kiran Mazumdar Shaw
| Organisation | Biocon Ltd |
| Headquarters | Bangalore |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Biocon Ltd
LIC Raises Stake in Biocon Amid Stock Decline - 18 Sep, 2024
Life Insurance Corporation of India increased its stake in Biocon to 5.023% through open market purchases. Despite this, Biocon's stock fell over 2% following the announcement.
LIC Boosts Stake in Biocon to 5.02% - 17 Sep, 2024
The Life Insurance Corporation of India has raised its stake in Biocon Ltd from 4.98% to 5.02%, acquiring additional shares in the open market. Biocon shares closed 3.90% lower at ₹375.50 on the BSE.
Biocon's Growth Strategy and Market Positioning Highlighted - 12 Sep, 2024
Kiran Mazumdar-Shaw reassures stakeholders about Biocon's independence and growth strategy while highlighting the company's success in the US insulin market amid potential shortages.
Biocon Ltd Continues Upward Trend - 11 Sep, 2024
Biocon Ltd shares rose 1.31% to Rs 391.65, marking a third consecutive session of gains. The stock has increased 46.52% over the past year, outperforming both NIFTY and Nifty Pharma index. Monthly gains stand at 15.92%, with trading volume above average.
Biocon Stock Surges on Positive Market Developments - 05 Sep, 2024
Biocon Ltd. experienced a significant rise, hitting a 30-month high amid reports of a potential GST tax cut on cancer drugs. The stock shows strong bullish trends and breakout patterns, indicating further upward momentum.
GST Council Meeting May Lower Cancer Drug Prices - 04 Sep, 2024
The upcoming GST council meeting is expected to reduce GST on cancer drugs from 12% to 5%, potentially making treatments more affordable, which could positively impact Biocon Ltd.
Biocon Secures Multiple USFDA Approvals, Shares Rise - 02 Sep, 2024
Biocon's subsidiary, Biocon Pharma, gained USFDA approvals for Sacubitril/Valsartan tablets and Daptomycin injection. An Establishment Inspection Report allows commercial supplies from a new facility. However, a GST penalty of Rs 40,000 was also imposed.
Biocon Subsidiary Secures USFDA Approval for Generic Drug - 01 Sep, 2024
Biocon Pharma, a subsidiary of Biocon, has received USFDA approval for Sacubitril/Valsartan Tablets, enhancing its portfolio of complex drug products for chronic heart failure treatment.
Biocon Achieves USFDA Approval and Gender Parity Goals - 31 Aug, 2024
Biocon's Executive Chairperson Kiran Mazumdar Shaw announced a target for gender parity by 2030. Additionally, Biocon Pharma received USFDA approval for Daptomycin injection, strengthening its US market presence.
Biocon Secures FDA Approvals for Key Products - 30 Aug, 2024
Biocon Ltd received FDA approval for its Vizag facility, allowing US supplies, and Biocon Pharma gained approval for Daptomycin injection, strengthening its product portfolio.
Biocon Secures Biosimilar Launch Agreement with Janssen - 29 Aug, 2024
Biocon Biologics has reached a settlement with Janssen to commercialize its biosimilar Bmab 1200 for autoimmune diseases in multiple regions, enhancing its immunology portfolio. The company reported a significant net profit increase of 550.59% year-over-year for Q1 FY25.
Insights on Biocon Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 8.57% to 8.69% in Jun 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 5.63% to 5.90% in Jun 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 135.5 Cr → 659.7 Cr (in ₹), with an average increase of 79.5% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 3.96K Cr → 4.59K Cr (in ₹), with an average increase of 13.8% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 60.64% of holdings in Jun 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Shree Ganesh Remedies Ltd has given 70.0% return, outperforming this stock by 36.9%
- NO EFFECT
Against Peers
In the last 3 years, Shree Ganesh Remedies Ltd has given 145.1% return, outperforming this stock by 144.2%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 19.73% to 18.89% in Jun 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, BIOCON stock has moved down by -3.4%
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 60.64% | 0.00 | |
| Foreign Institutions | 5.9% | 4.76 | |
| Mutual Funds | 8.69% | 1.45 | |
| Retail Investors | 18.89% | ||
| Others | 5.88% | 8.35 |
Key Indicators
Biocon Ltd Valuation
Biocon Ltd in the last 5 years
Lowest (24.48x)
March 19, 2024
Today (27.53x)
September 18, 2024
Industry (58.50x)
September 18, 2024
Highest (118.86x)
September 27, 2018
Earnings and Dividends
Biocon Ltd Earnings Results
Biocon Ltd’s net profit jumped 550.59% since last year same period to ₹659.70Cr in the Q1 2024-2025. On a quarterly growth basis, Biocon Ltd has generated 386.86% jump in its net profits since last 3-months.
Read More about Earnings ResultsBiocon Ltd Dividends May,2024
In the quarter ending March 2024, Biocon Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.55%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Biocon Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Biocon Ltd shares.
Biocon Ltd (BIOCON) share price today is ₹361.5
Biocon Ltd is listed on NSE
Biocon Ltd is listed on BSE
- Today’s highest price of Biocon Ltd is ₹369.
- Today’s lowest price of Biocon Ltd is ₹351.
PE Ratio of Biocon Ltd is 27.53
PE ratio = Biocon Ltd Market price per share / Biocon Ltd Earnings per share
Today’s traded volume of Biocon Ltd(BIOCON) is 63.51L.
Today’s market capitalisation of Biocon Ltd(BIOCON) is ₹43659.82Cr.
| Biocon Ltd(BIOCON | Price |
|---|---|
52 Week High | ₹395.8 |
52 Week Low | ₹217.5 |
Biocon Ltd(BIOCON) share price is ₹361.5. It is down -8.67% from its 52 Week High price of ₹395.8
Biocon Ltd(BIOCON) share price is ₹361.5. It is up 66.21% from its 52 Week Low price of ₹217.5
| Biocon Ltd(BIOCON | Returns |
|---|---|
1 Day Returns | -2.15% |
1 Month Returns | 5.47% |
3 Month Returns | 9.45% |
1 Year Returns | 33.11% |